Nicole Lamanna, MD

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna.

CLL17 finds fixed-duration venetoclax regimens match continuous ibrutinib at 3 years, boosting confidence in personalized frontline CLL choices.

Nicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.